Evoq Remedies (543500)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trailing P/E of 4.24 and PEG of 0.04 make the stock optically cheap if earnings are sustainable.
• Reported profit growth of 103.09% signals a strong earnings recovery from a prior low base.
• Piotroski F-score of 6/9 indicates reasonably healthy financials on the available data.
• Simple trading/distribution model is easy to understand and monitor.

Concerns

• Latest quarter had ₹26 Cr sales but zero net profit, so trailing earnings may not repeat.
• No sales growth (0.00%) and ROCE of only 0.35% point to poor capital productivity.
• Missing book value, debt/equity, and promoter holding data prevent a margin-of-safety calculation.
• At ₹9.44 (52-week high) with 0% dividend, there is no income cushion and downside risk is high.

AI Analysis

We are looking at Evoq Remedies, a small trading and distribution company with a market cap of just ₹24 crore. For a value investor, the most important question is not the multiple but the business behind it. At ₹9.44, near the top of its 52-week range, the stock appears cheap on a P/E of 4.24. But I have to ask: can this business earn consistently? Sales growth is 0.00%, and in the latest quarter it generated ₹26 crore of sales yet reported zero net profit. That is a red flag. A trader with no pricing power and thin margins can switch from profit to loss very quickly. The reported 103.09% profit growth and a PEG of 0.04 may sound tempting, but when the latest quarter shows nothing, I assume the growth came from a low base or bookkeeping year-over-year effects, not sustainable economics. ROCE of 0.35% confirms that the company is generating almost no return on capital. It is a no-moat business. There is no book value, debt/equity, or promoter holding data, so I cannot calculate a Graham-style margin of safety or judge whether insiders have skin in the game. The Piotroski F-score of 6/9 is the only encouraging signal, but it is not enough to overcome the lack of transparency and weak profitability. At the 52-week high, with no dividend yield, the buyer is dependent entirely on price appreciation and market sentiment. Graham would say: price is what you pay, value is what you get. Here, value is hard to find. The stock may be a cyclical trading vehicle, but it is not a compounding machine. I will not be a buyer until I see consistent operating profits, working capital discipline, and full financial disclosure.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer